Calamos Advisors
LGND icon

Calamos Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Calamos Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.09M Buy
22,435
+1,575
+8% +$371K 0.02% 494
2026
Q1 		$4.16M Sell
20,860
-185
-0.9% -$36.6K 0.01% 587
2025
Q4 		$3.98M Buy
21,045
+312
+2% +$59.9K 0.01% 559
2025
Q3 		$3.67M Buy
20,733
+8,522
+70% +$1.27M 0.01% 579
2025
Q2 		$1.39M Sell
12,211
-7,723
-39% -$825K 0.01% 666
2025
Q1 		$2.1M Buy
19,934
+5,519
+38% +$624K 0.01% 587
2024
Q4 		$1.54M Sell
14,415
-49
-0.3% -$5.54K 0.01% 630
2024
Q3 		$1.45M Buy
14,464
+3,617
+33% +$364K 0.01% 639
2024
Q2 		$914K Buy
10,847
+1,812
+20% +$144K ﹤0.01% 657
2024
Q1 		$660K Buy
9,035
+4,449
+97% +$328K ﹤0.01% 684
2023
Q4 		$328K Buy
+4,586
New +$271K ﹤0.01% 735
2023
Q3 		– Sell
-12,619
Closed -$910K – 966
2023
Q2 		$910K Sell
12,619
-11,077
-47% -$831K ﹤0.01% 716
2023
Q1 		$1.74M Buy
23,696
+7,774
+49% +$553K 0.01% 757
2022
Q4 		$1.06M Buy
+15,922
New +$1.04M 0.01% 851
2019
Q1 		– Sell
-2,453
Closed -$208K – 685
2018
Q4 		$208K Hold
2,453
– – ﹤0.01% 659
2018
Q3 		$420K Buy
+2,453
New +$370K ﹤0.01% 606

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Calamos Advisors's LGND Position: Q2 2026 in Review

Calamos Advisors increased its Ligand Pharmaceuticals (LGND) stake by 7.6% in Q2 2026, buying an estimated $371K and bringing the position to 22,435 shares worth $7.09M. The position accounts for 0.02% of the portfolio, ranked #494.

Calamos Advisors first reported a position in LGND in Q3 2018 and has held it in 16 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Calamos Advisors held 22,435 shares of Ligand Pharmaceuticals worth $7.09M as of Q2 2026.
  • Calamos Advisors bought 1,575 Ligand Pharmaceuticals shares in Q2 2026, an estimated $371K.
  • Ligand Pharmaceuticals made up 0.02% of Calamos Advisors's portfolio in Q2 2026, its #494 holding.
  • Calamos Advisors first reported a position in Ligand Pharmaceuticals in Q3 2018 and has held it in 16 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.